Humacyte (HUMA) Preferred Stock Liabilities (2020 - 2021)
Humacyte (HUMA) reported Preferred Stock Liabilities of $421.0 million for Q2 2021, little changed quarter-over-quarter from $421.0 million in Q1 2021.
Humacyte (HUMA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Humacyte (HUMA) has 2 years of Preferred Stock Liabilities data on file, last reported at $421.0 million in Q2 2021.
- Preferred Stock Liabilities for Q2 2021 came in at $421.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2021 was $421.0 million (changed N/A YoY), and the FY2020 annual result was $421.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $421.0 million in Q2 2021 per HUMA's latest filing, from $421.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $421.0 million in Q3 2020 and troughed at $421.0 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Humacyte | 183.21 Mn | 134.67 Mn | -1.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 420.99 Mn |
| Mar 31, 2021 | 420.99 Mn |
| Dec 31, 2020 | 420.99 Mn |
| Sep 30, 2020 | 420.99 Mn |